Pain Ther. 2017 Jun 19. doi: 10.1007/s40122-017-0075-4.
[Epub ahead of print]
Abstract
The identification of a number of families of lipid signal molecules since the 1990s created new therapeutic possibilities for a great number of disorders characterized by chronic inflammation and pain. These lipid autacoids have been explored in a great variety of animal models related to inflammation, pain, (neuro-)protection, and repair. Based on the data from these models, as well as on a number of proof of principle studies in the clinic in indications such as neuropathic pain, a new chapter in medicine is about to begin. We would like to introduce the term “Autacoid Pain Medicine” for this chapter. There are, however, a number of methodological and strategic issues to overcome in this field. One of the roadblocks is related to patent strategies around families of these molecules. As this is not always recognized we will present a number of examples.
KEYWORDS:
ALIAmides; Analgesia; Autacoids; Endocannabinoids; Lipoxins; Pain; Palmitoylethanonolamide; Phospholipids; Protectins; Resolvins; Treatment
- PMID: 28631063
- DOI: 10.1007/s40122-017-0075-4
-
Publication type